Currently, a number of studies have shown that CXCR7 can be used as a therapeutic target for prostate cancer, and the progression and metastasis of prostate cancer can be inhibited by targeting CXCR7 (Zheng et al., 2013; Mir et al., 2016; Bai et al., 2019; Zhang Y. et al., 2025). Here, ACKR3 is linked to prostate cancer.